Fractyl Health at Morgan Stanley conference: revita nears key data

On 14 September 2026, Fractyl Health made a presentation at the Morgan Stanley Global Healthcare Conference to assert that its Revita therapy could fill an empty niche left by GLP-1 drugs. These drugs have enabled many patients to shed weight, but a significant issue remains when the treatment ceases. Fractyl estimates that around 1 million Americans discontinue GLP-1 therapy each month, creating a vast and expanding market for post-GLP-1 weight maintenance.

Revita is an outpatient endoscopic procedure that lasts approximately one hour and employs a unique catheter-based system to ablate the duodenum, the initial segment of the small intestine responsible for nutrient sensing and absorption. The goal is to restore normal nutrient signaling in individuals with obesity and type 2 diabetes. Unlike a continuous drug, the procedure aims to achieve a more enduring metabolic reset through a single intervention.

The pivotal REMAIN-1 study has gathered data from over 300 patients who had shed more than 15% of their body weight on tirzepatide before halting treatment and were subsequently assigned to Revita or a sham procedure in a 2:1 ratio. All participants have completed their 6-month follow-up visits. The trial is currently in the data-cleaning phase, with its design being double-blind.

The study utilizes two primary endpoints: weight regain at 6 months and durability at one year after discontinuing GLP-1 therapy. Fractyl aims for at least 50% of patients to maintain a 5% overall body weight loss one year following cessation of GLP-1 therapy. They are also examining enrichments subgroups, such as patients with higher initial weight loss and longer ablation lengths, to enhance their chances of success.